NYDRAZID
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1952
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NYDRAZID is an injectable medication approved in 1952 by Novartis with an unknown mechanism of action and indication profile. The specific therapeutic area and patient population cannot be determined from available data, but the product's 72-year tenure suggests a legacy indication in infectious disease or immunology.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating a contracting team focused on transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NYDRAZID offers limited career growth opportunities given zero linked job openings and imminent loss of exclusivity. Roles on this product typically focus on managing decline, optimizing supply chains, and transitioning to generic or alternative therapies rather than driving expansion.
Brand ManagerSales Director
Worked on NYDRAZID at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.